Covidien, the Bermuda-based healthcare products company that is one of the largest life sciences companies in Massachusetts, said today it is implementing a restructuring program that includes projects in all four of its business segments and in corporate. The company didn’t disclose any job cuts, although it said it plans to take a $200 million charge for the program, and that it will save $50 million to $75 million a year once it is completed. Covidien’s four business lines are medical devices, imaging solutions, pharmaceutical products, and medical supplies.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
